The benefits of Robotic Magnetic Navigation (RMN) have been validated by >100 leading hospitals globally treating >100,000 patients. The improvements in outcomes have been demonstrated with scientific rigor in hundreds of scientific publications.
Studies have found 72% fewer major complications when using RMN vs manual catheters1
Clinical data suggests a 71% reduction in cardiac perforations during robotic ablation procedures1
Robotics enables physicians to treat complex arrhythmias that are difficult or may be impossible to treat otherwise.
RMN allows physicians to treat complex arrhythmias and certain patients that would otherwise not be good candidates for a cardiac ablation or cannot be treated with manual catheters.
Adopting cutting-edge robotic technology allows for competitive differentiation and showcasing of your clinical and technological leadership in the community. Stereotaxis is committed to supporting Robotic EP practices in attracting and educating patients and referral physicians.
A single adverse event can cause significant direct and indirect expenses: treatment costs, extended hospital stays, increased insurance and legal expenses, reputational damage, and more. A robust body of evidence demonstrates RMN can reduce adverse events.1
Operating rooms expose your team to workplace hazards that increase the risk of cancer and orthopedic injury2,3,4. Injuries and missed work days can increase operating costs, lead to missed revenue opportunities, increase insurance and legal expenses, and cause treatment delays for patients. With RMN, physicians perform procedures seated without lead and protected from radiation.
RMN procedures are often performed by a single physician with less support required. This differs from manual procedures where the physician is scrubbed in and requires skilled technicians or secondary physicians to manage mapping and ECG systems. Freeing up your staff can increase revenue opportunities and reduce operating costs.
Studies have shown that complex procedures can be performed faster with RMN. A large 779 patient meta-analysis showed a statistically significant reduction of 26 minutes for VT procedures using RMN5. Some RMN users have performed up to 6 ablations in a day using the system.
The cost to establish a Robotic EP program has been significantly reduced with recent innovations. By offering a fully integrated robotic lab including fluoroscopy, a Robotic EP lab can be established at a price similar to a high-end biplane x-ray alone.
The cost of a robotic disposable used in each procedure is often more than counteracted by savings from the reduced use of other disposables such as expensive sheaths, diagnostic catheters or other disposables. While the use of disposable products in ablation procedures varies, we can help you identify ways to reduce disposable costs without compromising patient care.
You operate in a competitive marketplace and cater to a range of stakeholders. The strategic differentiation offered from establishing a cutting-edge RoboticEP program can be critical to:
- Data on file as shown on http://www.roboticep.com/clinical-data/
- Roguin A, Goldstein J, Bar O, Goldstein JA. Brain and neck tumors among physicians performing interventional procedures. Am J Cardiol. 2013;111(9):1368-72.
- Vano E, Leiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities in catheterization personnel: results of a survey and direct assessments. J Vasc Interv Radiol. 2013;24(2):197-204
- Klein LW, Tra Y, Garratt KN, Powell W, Lopez-Cruz G, Chambers C, et al. Occupational health hazards of interventional cardiologists in the current decade: Results of the 2014 SCAI membership survey. Catheter Cardiovasc Interv. 2015;86(5):913-24
- Turagam MK, Atkins D, Tung R, Mansour M, Ruskin J, Cheng J, et al. A meta-analysis of manual versus remote magnetic navigation for ventricular tachycardia ablation. J Interv Card Electrophysiology. 2017 Sept;49(3):227-235.
Stereotaxis Intended Use Statements, United States Labeling:
The Genesis RMN® and Niobe® ES Systems are intended to navigate compatible magnetic devices through tissue to designated target sites in the right and left heart, coronary vasculature, neurovasculature, and peripheral vasculature by orienting the device tip in a desired direction. The Cardiodrive® Catheter Advancement System (CAS) is intended to automatically advance and retract compatible magnetic electrophysiology (EP) mapping and ablation catheters inside a patient’s heart when used in conjunction with a Stereotaxis magnetic navigation system. The Cardiodrive System is not intended to advance the EP mapping and ablation catheters through the coronary vasculature or the coronary sinus.
Consult the associated product labeling for the Indications for Use and instructions of other devices used in conjunction with Stereotaxis products.
Cardiodrive and Niobe are trademarks of Stereotaxis, Inc., registered in the United States, the European Community, and Japan. Genesis RMN is a trademark of Stereotaxis, Inc., registered in the United States.